Why the study?
Does microaxial pump-supported coronary artery bypass (MPCAB) reduce death and MACE compared to conventional CPB-CABG in patients with severely impaired left ventricular function?
Does microaxial pump-supported coronary artery bypass (MPCAB) reduce death and MACE compared to conventional CPB-CABG in patients with severely impaired left ventricular function?
Answers are grounded in this paper and cite their sources.
Microaxial pump-supported CABG without cardiopulmonary bypass significantly reduces the risk of death and MACE compared to conventional CPB-CABG in patients with severely impaired left ventricular function.
MPCAB allows for complete surgical revascularization without the necessity of extracorporeal circulation in spite of severely impaired left ventricular function. This first comparative study on the outcome after MPCAB versus CPB-CABG demonstrates a significantly decreased risk of death as well as MACE in MPCAB patients. The MPCAB concept expands the spectrum of patients eligible for CABG without CPB towards patients with severely impaired left ventricular function.
No takes yet. Share an insight, caveat, or question.
Assmann et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: